Researchers in the UK and the United States have found that a drug composed of an antibody carrying a highly toxic anti-cancer agent is well tolerated by patients at much higher doses than have been used before, according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague on Friday.
Researchers at the University of Illinois at Chicago College of Pharmacy are attempting to discover how genes determine how well an antipsychotic medication works in adults and children and the side effects it will cause.
Researchers at the Cancer Treatment Centers of America found that antioxidant therapies such as green tea extract, melatonin, high-potency multivitamins, vitamin C and vitamin E do not interfere with radiation treatment.
The key to combating AIDS in Russia may be to treat HIV-infected drug users. A new model estimating the spread of HIV in Russia suggests that treating injection drug users with antiretroviral medication will slow transmission of the virus among the general population.
A simple points system may soon help guide treatment of elderly heart failure patients. Researchers at Washington University School of Medicine in St. Louis found that by counting how many of seven easy-to-obtain health factors a patient has, physicians can estimate the patient’s risk of dying.
Too much of a signaling protein called insulin-like growth factor-I (IGF-I) may fan the flames of cancer, while too little of the protein may cause short stature, dementia and osteoporosis. New research investigates how the growth hormone/IGF system is affected by the important tumor suppressor gene p53. This interplay of two signaling pathways reinforces questions about the long-term risks of prescribing growth hormone, while suggesting a future new avenue for cancer therapy.
Scientists in Australia have discovered that in acute lymphoblastic leukemia (ALL) there are “good” and “evil” clones of the same type of ALL cell. The “evil” cells are clones that have a pre-existing resistance to drugs used for treating ALL, and their presence in a patient means that person will inevitably relapse after chemotherapy, according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Preliminary results from a phase II clinical trial have provided the first evidence that treating people with kidney cancer with bevacizumab and erlotinib before surgery is safe, effective and may prolong patients’ survival, the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics heard on Thursday.
Overall, the use of drugs that reduce stomach acid, such as H2 blockers and proton pump inhibitors, do not increase the risk of cancer of the esophagus or stomach, but it is informed that cancer risk is probably due to underlying conditions.
IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted a Marketing Authorization Application (MAA) in eCTD format (electronic common technical document) to the European Medicines Agency (EMEA) for Mepact (mifamurtide for injection), requesting approval for its use in the treatment of patients with newly diagnosed resectable high-grade osteosarcoma following surgical resection in combination with post-operative multi-agent chemotherapy. This announcement follows the October 25, 2006 submission of a New Drug Application (NDA) for Junovan (mifamurtide for injection) to the Food and Drug Administration (FDA) in the United States.